Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | GCK | P35557 | 7/20 | 0.41 |
| ▸ | GCKR | Q14397 | 6/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005733 | 0.98 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10TDP1NOS3 | |
| SCHEMBL2643602 | 0.80 | KDM4E (0.67) | KDM4ETDP1NOS3NOS2GCK | |
| SCHEMBL30565567 | 0.78 | KDM4E (0.64) | KDM4ENOS3NOS2GCKGCKR | |
| SCHEMBL1700622 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10TDP1NOS3 | |
| SCHEMBL597932 | 0.78 | KDM4E (0.64) | KDM4ENOS3NOS2GCKGCKR | |
| Hydrochloric Acid SCHEMBL27585913 | 0.77 | KDM4E (0.96) | KDM4EALDH1A1HSD17B10TDP1NOS3 | |
| SCHEMBL17509 | 0.76 | SMN1; SMN2 (0.56) | ALDH1A1HSD17B10TDP1SMN1; SMN2 | |
| SCHEMBL29483829 | 0.76 | SMN1; SMN2 (0.56) | ALDH1A1HSD17B10TDP1SMN1; SMN2 | |
| SCHEMBL651902 | 0.75 | ALDH1A1 (0.71) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL23625111 | 0.75 | KDM4E (0.60) | KDM4ENOS3NOS2GCKGCKR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110678176-B | Sulfonamide substituted cyanopyrrolidines with DUB inhibitor activity | 特殊治疗有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2022220725-A1 | LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS | ZAMARATSKI EDOUARD (SE) | 2022-10-20 | — | — | WO | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| US-11414402-B2 | Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-08-16 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-6673787-B2 | PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| US-6638964-B2 | Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents | EISAI CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-6469043-B1 | ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY | EISAI CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | KDM4E 175/4885ALDH1A1 300/4885HSD17B10 1270/4885 |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | KDM4E 1202/4885ALDH1A1 417/4885HSD17B10 3128/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | KDM4E 175/4885ALDH1A1 300/4885HSD17B10 1270/4885 |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | KDM4E 1229/4885ALDH1A1 422/4885HSD17B10 3167/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | KDM4E 2279/4885ALDH1A1 1266/4885HSD17B10 2146/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | KDM4E 1771/4885ALDH1A1 1018/4885HSD17B10 1768/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | KDM4E 178/4885ALDH1A1 285/4885HSD17B10 1114/4885 |
| US-11414402-B2 | Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors | USP30, USP1, USP39 | KDM4E 1133/4885ALDH1A1 560/4885HSD17B10 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.